Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
301015.SZ
STRONG BUYGet insider-trade alertsQingdao Baheal Medical INC. · Healthcare · China · $1.5B · Avg Vol: $17M/d
COMPANY DESCRIPTION
Qingdao Baheal Medical Inc. provides comprehensive healthcare commercialization services, specializing in brand operations, marketing, and distribution for pharmaceutical and medical device companies. The company acts as a vital bridge for multinational healthcare brands entering or expanding in the Chinese market, leveraging its extensive hospital and pharmacy network. Its competitive moat is sustained by its data-driven marketing platforms and deep regulatory navigation expertise.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.2B | 1.2B | 1.1B | -0.0% | 1.1B | 1.1B | 1.2B | 6.0% |
| EPS | 0.14 | 0.20 | 0.19 | 0.13 | -2.1% | 0.14 | 0.14 | 0.22 | 29.5% |
| Shares | 525.1M | 525.6M | 525.6M | 525.6M | +0.1% | 525.6M | — | — | — |
| Debt | 197.0M | 214.2M | 351.3M | 497.8M | 36.2% | 561.7M | — | — | — |
| Equity | 339.0M | 425.8M | 349.8M | 362.8M | 2.3% | — | — | — | — |
| Op CF | 45.0M | 117.8M | 119.9M | 137.6M | 45.1% | 96.8M | — | — | — |
| Inv CF | -17.3M | -43.6M | -107.9M | -86.7M | — | — | — | — | — |
| Fin CF | -80.1M | -49.1M | 0.7M | 53.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 301015.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 301015.SZ | Qingdao Baheal Medical INC.(you) | $1.5B | 86 | STRONG BUY |
| 600056.SS | China Meheco Group Co., Ltd. | $1.9B | 80 | BUY |
| 000028.SZ | China National Accord Medicines Corporation Ltd. | $1.7B | 96 | STRONG BUY |
| 0874.HK | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.9B | 85 | STRONG BUY |
| 603368.SS | Guangxi LiuYao Group Co., Ltd | $854M | 92 | STRONG BUY |
| 600998.SS | Jointown Pharmaceutical Group Co., Ltd | $3.4B | 80 | BUY |
| 600511.SS | China National Medicines Corporation Ltd. | $2.9B | 98 | STRONG BUY |
| 2607.HK | Shanghai Pharmaceuticals Holding Co., Ltd | $5.5B | 97 | STRONG BUY |
| 1099.HK | Sinopharm Group Co. Ltd. | $6.3B | 96 | STRONG BUY |
| 000950.SZ | C.Q. Pharmaceutical Holding Co., Ltd. | $1.3B | 51 | HOLD |
Peer medians: ROE 4.8% · P/E 26.5x · Gross margin 52.5%